Lilly price break reverses NICE’s 'No' ruling on breast cancer drug Verzenio

England’s drug-cost watchdogs initially told Eli Lilly that its CDK 4/6 inhibitor to treat breast cancer, Verzenio, wasn't cost-effective compared to rivals from Pfizer and Novartis. So Lilly dished up a new price break—and now NICE is on board.